Zobrazeno 1 - 10
of 1 767
pro vyhledávání: '"FcRn"'
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Numerous clinical trials for myasthenia gravis (MG) treatment have been conducted recently, with satisfactory cognitive and clinical results. However, due to the limited evidence for direct comparison of the safety and effectiveness of vario
Externí odkaz:
https://doaj.org/article/635760d57f0e4a8d9c8b35c4c7674581
Autor:
Shaoju Qian, Ruixue Li, Yeqing He, Hexi Wang, Danqiong Zhang, Aiping Sun, Lili Yu, Xiangfeng Song, Tiesuo Zhao, Zhiguo Chen, Zishan Yang
Publikováno v:
Microbial Cell Factories, Vol 23, Iss 1, Pp 1-14 (2024)
Abstract Background Herpes simplex virus type 1 (HSV-1) is a major cause of viral encephalitis, genital mucosal infections, and neonatal infections. Lactococcus lactis (L. lactis) has been proven to be an effective vehicle for delivering protein anti
Externí odkaz:
https://doaj.org/article/f2e1ef0a4c7b476bac2d6b0e7381ac19
Publikováno v:
BMC Neurology, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Generalized myasthenia gravis (gMG) can be managed with acetylcholinesterase inhibitors (AChEis; e.g., pyridostigmine), corticosteroids, other immunosuppressive drugs (e.g., tacrolimus), and their combinations. Intravenous immunog
Externí odkaz:
https://doaj.org/article/215a37aa495e4c0187f2b758a7de23f8
Publikováno v:
Exploration of Immunology, Vol 4, Iss 3, Pp 341-357 (2024)
Aim: The clinical symptoms of autoantibody (AAb)-mediated autoimmune diseases (AID) usually correlate with the AAb-titer. Immunoglobulins (Igs) of the IgG type are actively recycled by the neonatal crystallizable fragment receptor (FcRn). The most co
Externí odkaz:
https://doaj.org/article/b0c98814b355482e8fd77f52d100a9d0
Autor:
Kohei Togami, Whitney Wolf, Lucas C. Olson, Madison Card, Limei Shen, Alison Schaefer, Kenichi Okuda, Larry Zeitlin, Michael Pauly, Kevin Whaley, Raymond J. Pickles, Samuel K. Lai
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Effective treatment and immunoprophylaxis of viral respiratory infections with neutralizing monoclonal antibodies (mAbs) require maintaining inhibitory concentrations of mAbs at the airway surface. While engineered mAbs with increased affinity to the
Externí odkaz:
https://doaj.org/article/1ce0586831914fc7af05bae7e4c1ab5f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
Monoclonal antibodies (mAbs) as therapeutics necessitate favorable pharmacokinetic properties, including extended serum half-life, achieved through pH-dependent binding to the neonatal Fc receptor (FcRn). While prior research has mainly investigated
Externí odkaz:
https://doaj.org/article/8e21d7845285420f8c4d1cd91773b5b4
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
ABSTRACTRecent development of amyloid-β (Aβ)-targeted immunotherapies for Alzheimer’s disease (AD) have highlighted the need for accurate diagnostic methods. Antibody-based positron emission tomography (PET) ligands are well suited for this purpo
Externí odkaz:
https://doaj.org/article/e26e8d4cee664eda81a36e31dae1d509
Autor:
Kristina M.J. Aertker, Minu Ravindra Pilvankar, Tobias M. Prass, Michaela Blech, Fabian Higel, Srinath Kasturirangan
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
ABSTRACTBispecific antibodies (BsAbs) capable of recognizing two distinct epitopes or antigens offer promising therapeutic options for various diseases by targeting multiple pathways. The favorable pharmacokinetic (PK) properties of monoclonal antibo
Externí odkaz:
https://doaj.org/article/1c603c903ef24f8ab169d4e15eb01906
Autor:
Omar S. Qureshi, Emma J. Sutton, Rosemary F. Bithell, Shauna M. West, Rona M. Cutler, Gillian McCluskey, Graham Craggs, Asher Maroof, Nicholas M. Barnes, David P. Humphreys, Stephen Rapecki, Bryan J. Smith, Anthony Shock
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
ABSTRACTRozanolixizumab is a humanized anti-neonatal Fc receptor (FcRn) monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4) sub-class, currently in clinical development for the treatment of IgG autoantibody-driven diseases. This format is frequ
Externí odkaz:
https://doaj.org/article/f74b0a47f067425f9e3ed7abc893041a